News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

InNexus Inc. Announces Publication Of Scientific Review Of TransMab(TM) Technology

10/19/2005 5:13:14 PM

VANCOUVER, April 7 /PRNewswire-FirstCall/ -- InNexus Biotechnology Inc., a company empowering the monoclonal antibody, announces the publication of an invited review on TransMab(TM) technology. TransMabs(TM) are monoclonal antibodies to intracellular targets, modified by SuperAntibody Technology ("SAT") to penetrate or translocate into cells, bind to their targets and regulate cellular activities. This technology is the subject of a recently announced collaboration between InNexus and Epitomics, a company using rabbit monoclonal antibodies to create novel diagnostics and therapeutics. The review written by Muller, S., Zhao, Y. Brown, T. L. et al. and entitled "TransMabs: Cell-penetrating antibodies, The next generation" has recently been published in "Expert Opinion on Biological Therapy, volume 5 (2), 2005 pages 237 to 241." It is available online at

Commenting on the announcement, Dr. Heinz Kohler, Vice Head of SuperAntibody Research and Development at InNexus, added: "the publication of this review is an acknowledgement of the interest in and novelty of the TransMab(TM) technology." Dr. Charles Morgan, President & CEO of the Company stated, "It is important for the Company to disclose its progress in a peer-reviewed forum so that both the scientific, financial and corporate communities can be apprised of the ongoing validation of SAT. This is a first step in a peer-reviewed process leading to the clinical development and eventually the marketing of this totally new use of monoclonal antibodies. Further announcements will be forthcoming on both internal InNexus and sponsored research and progress towards therapeutic application."

About InNexus

InNexus Biotechnology Inc. is an innovative antibody-driven drug development company that has developed two technology platforms, SuperAntibody(TM) and TransMabs(TM), which respectively improve the potency of existing antibody products and create a novel class of antibody based drug which can penetrate into cells. Both product platforms utilize InNexus's unique, novel and patented methods and technologies allowing InNexus (and its strategic partners) to advance novel drug therapeutics and diagnostics to create new markets within multiple disease areas. To learn more about InNexus please visit

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are not historical facts and are subject to risks and uncertainties which could cause actual results and the timing of certain events to differ materially from those set forth in or implied herein including, without limitation, risks associated with clinical development, regulatory approvals, product commercialization, intellectual property claims litigation and other risks associated with the Company's proposed activities.

On behalf of the Board of Directors of InNexus Biotechnology, Inc. "ALTON C. MORGAN" Dr. A. Charles Morgan President Investor Relations: Toll-free: 1-866-990-8382 or 1-888-271-0788 The TSX Venture Exchange has neither approved nor disapproved of the information contained herein.

InNexus Biotechnology, Inc.

CONTACT: Investor Relations: Toll-free: 1-866-990-8382 or1-888-271-0788,

Read at

comments powered by Disqus